You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Lixte terminates license agreement with Taipei Medical University
Brazil Pay TV Down Record Amount In 2019, With Losses Continuing In Q1'20
Impact of COVID 19 on US Video Entertainment Trends
Case Study: Transforming Sales Enablement Data at a Global Advertising and Media Firm
Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19
Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.